A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants
KN056 demonstrated favorable PK, PD, and safety profiles in healthy Chinese participants, supporting its potential for once-weekly dosing.
Authors
- Qi Pei (ORCID: https://orcid.org/0000-0002-6711-4251)
- Jinlian Xie (ORCID: https://orcid.org/0000-0003-1936-371X)
- Chang Cui
- Yuanfang Qin
- Guoping Yang (ORCID: https://orcid.org/0000-0001-5930-586X)
- Wen-Qiao Huang
- Jie Huang (ORCID: https://orcid.org/0009-0007-4279-2914)
- Yuwei Li (ORCID: https://orcid.org/0000-0002-5488-242X)
- Li Li (ORCID: https://orcid.org/0000-0003-4229-4310)
- Wen‐Hua Zhang (ORCID: https://orcid.org/0000-0001-9047-8881)
- Haonan Zhang (ORCID: https://orcid.org/0000-0002-9467-2566)
- Shuang Yang (ORCID: https://orcid.org/0000-0002-1607-7446)
Institutions
- Central South University (CN)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1080/13543784.2025.2500303
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China